Pharmaceutical composition of ornithine aspartate

Abstract

The invention discloses a pharmaceutical composition of ornithine aspartate. By fusing, mixing and preparing ornithine aspartate and a proper amount of PLGA and PEG6000, the ideal slow-release effectcan be achieved. The pharmaceutical preparation prepared from the pharmaceutical composition of ornithine aspartate is slowly released, a patient just needs to take the medicine once a day, the patient compliance is high, the stable blood concentration can be maintained, the side effect is small, and the effect is good; the consumption of auxiliary materials is low, the preparation technology is simple, and the composition is suitable for technological production.

Description

technical field [0001] The invention relates to a pharmaceutical composition of ornithine aspartate. Background technique [0002] Ornithine aspartate can provide substrates for the synthesis of urea and glutamine. Glutamine is the detoxification product of ammonia, and it is also the storage and transportation form of ammonia; under physiological and pathological conditions, the synthesis of urea and glutamine Amide synthesis is affected by ornithine, aspartate, and other dicarboxylic compounds. Ornithine is almost involved in the whole process of urea cycle activation and ammonia detoxification. In the process, arginine is formed, which in turn splits off urea to form ornithine. Aspartic acid participates in the synthesis of nucleic acid in liver cells to facilitate the repair of damaged liver cells. In addition, due to the indirect promotion effect of aspartic acid on the metabolism process of tricarboxylic acid cycle in liver cells, the energy generation in liver cell...

AI Technical Summary

Problems solved by technology

The marketed ornithine-aspartate preparation needs to be administered several times a day, which is inconvenient to use

Patent CN103705490A discloses a sustained-release preparation of ornithine aspartate to solve the problem, but its adjuvant content is high, and the oral administration dose of ornithine aspartate itself is relatively large (every 3g of granules) , adding more excipients is more likely to lead to difficulty in taking medicine; and blank ball cores are required to prepare drug-containing tablet cores, which is costly and complicated.

Images